Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05886049 2026-04-15

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

24 enrolled

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07441694 2026-04-15

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

218 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06034470 2026-04-14

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

30 enrolled

Phase 1 Not yet recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT07527221 2026-04-14

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

40 enrolled

Phase 1 Not yet recruiting

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT07529951 2026-04-14

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

60 enrolled

Polycythemia Vera, Primary Myelofibrosis

NCT02381886 2026-04-13

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

CNSGastrointestinalMyeloidOther hematologic neoplasm

166 enrolled

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03816319 2026-04-13

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Classical hematologyMyeloidOther hematologic neoplasm

42 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06047886 2026-04-13

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

50 enrolled

Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

NCT06146257 2026-04-13

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06484062 2026-04-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

54 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06656494 2026-04-13

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

266 enrolled

Phase 1 Enrolling by invitation

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Phase 1 Suspended

30 enrolled

Myelodysplastic Syndromes

NCT06021600 2026-04-09

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Phase 1 Terminated

3 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05088356 2026-04-08

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

77 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05473910 2026-04-08

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

75 enrolled

Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Phase 1 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07254793 2026-04-07

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

94 enrolled

Lymphoma, Non-Hodgkin, Motor Activity, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05263271 2026-04-06

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 1 Terminated

58 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06313593 2026-04-06

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

186 enrolled

Myeloproliferative Disorders, Primary Myelofibrosis

NCT07008118 2026-04-06

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

120 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04024761 2026-04-03

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

50 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT00720785 2026-04-01

Natural Killer Cells and Bortezomib to Treat Cancer

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05304377 2026-04-01

CML

250 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06327685 2026-04-01

Avapritinib With Decitabine in Patients With SM-AHN

34 enrolled

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT07469891 2026-03-31

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

100 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT04318678 2026-03-30

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

108 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

210 enrolled

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05933070 2026-03-30

LAUREL

Phase 1 Terminated

2 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05552469 2026-03-27

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

62 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT07020533 2026-03-27

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

46 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03533816 2026-03-25

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

38 enrolled